Cadent Therapeutics Inc. and Novartis AG have described cyclopental[c]pyrrol glutamate receptor ionotropic, NMDA 2B (GRIN2B; GluN2B) negative allosteric modulators reported to be useful for the treatment of pain, autism, tinnitus, anxiety disorders, Rett syndrome, Parkinson's disease, migraine and major depression.